0001203311-17-000006.txt : 20170208
0001203311-17-000006.hdr.sgml : 20170208
20170208172950
ACCESSION NUMBER: 0001203311-17-000006
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20170206
FILED AS OF DATE: 20170208
DATE AS OF CHANGE: 20170208
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: SEATTLE GENETICS INC /WA
CENTRAL INDEX KEY: 0001060736
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 911874389
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 21823 30TH DRIVE SE
STREET 2: SUITE
CITY: BOTHELL
STATE: WA
ZIP: 98021
BUSINESS PHONE: 4255274000
MAIL ADDRESS:
STREET 1: 21823 30TH DRIVE SE
STREET 2: SUITE
CITY: BOTHELL
STATE: WA
ZIP: 98021
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: SIEGALL CLAY B
CENTRAL INDEX KEY: 0001167496
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-32405
FILM NUMBER: 17583598
MAIL ADDRESS:
STREET 1: 21823 30TH DR SE
CITY: BOTHELL
STATE: WA
ZIP: 98021
4
1
edgardoc.xml
PRIMARY DOCUMENT
X0306
4
2017-02-06
0
0001060736
SEATTLE GENETICS INC /WA
SGEN
0001167496
SIEGALL CLAY B
21823 30TH DRIVE SE
BOTHELL
WA
98021
1
1
0
0
President and CEO
Common Stock
2017-02-06
4
M
0
4042
10.2
A
640477
D
Common Stock
2017-02-06
4
S
0
4042
61.13
D
636435
D
Common Stock
2017-02-06
4
M
0
10323
10.29
A
646758
D
Common Stock
2017-02-06
4
S
0
10323
61.69
D
636435
D
Common Stock
2017-02-06
4
M
0
100
10.29
A
636535
D
Common Stock
2017-02-06
4
S
0
100
62.51
D
636435
D
Non-Qualified Stock Option (right to buy)
10.2
2017-02-06
4
M
0
4042
0.0
D
2017-05-25
Common Stock
4042
12123
D
Non-Qualified Stock Option (right to buy)
10.29
2017-02-06
4
M
0
10323
0.0
D
2017-08-28
Common Stock
10323
62628
D
Non-Qualified Stock Option (right to buy)
10.29
2017-02-06
4
M
0
100
0.0
D
2017-08-28
Common Stock
100
62528
D
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.
Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $60.56 to $61.44. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.
Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting.
Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $61.44 to $62.35. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.
Shares vested at a rate of 25% on 5/25/08 and monthly thereafter until all the shares were fully vested on 5/25/11.
Shares vested at a rate of 25% on 8/28/08 and monthly thereafter until all the shares are fully vested on 8/28/11.
/s/ Clay Siegall
2017-02-08